Category Archives: Psoriasis

Mild To Moderate Plaque Psoriasis Market Insight, Epidemiology and Market Forecast 2030

The global Mild To Moderate Plaque Psoriasis is projected to grow from USD xx mllion in 2020 to USD xx million by 2027, at a CAGR of xx% from 2021 to 2030. The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the markets historic and forecast market growth by geography.

Key Questions Answered in Market Report:-

Get sample copy of thisreport @

https://www.infinitybusinessinsights.com/request_sample.php?id=473646

TOP Key Players @ Allergan, Johnson and Johnson, Amgen, Abbvie, Eli Lilly, Dermira Inc., Novartis, Galectin Therapeutics, Cellceutix Corporation and Biogen Inc., Bayer

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of Mild To Moderate Plaque Psoriasis market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

Global Mild To Moderate Plaque Psoriasis Market: Regional Segment Analysis

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they Mild To Moderate Plaque Psoriasis Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key factors driving the Global Mild To Moderate Plaque Psoriasis Market?

What are the key market trends impacting the growth of the Global Mild To Moderate Plaque Psoriasis Market?

What are the challenges to market growth?

Who are the key vendors in the Global Mild To Moderate Plaque Psoriasis Market?

What are the market opportunities and threats faced by the vendors in the Global Mild To Moderate Plaque Psoriasis Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia Mild To Moderate Plaque Psoriasis Market;

3.) The North American Mild To Moderate Plaque Psoriasis Market;

4.) The European Mild To Moderate Plaque Psoriasis Market;

5.) Market entry and investment feasibility;

6.) The report conclusion.

All the research report is made by using two techniques that are Primary and secondary research. There are various dynamic features of the business, like client need and feedback from the customers. Before (company name) curate any report, it has studied in-depth from all dynamic aspects such as industrial structure, application, classification, and definition.

The report focuses on some very essential points and gives a piece of full information about Revenue, production, price, and market share.

Mild To Moderate Plaque Psoriasis Market report will enlist all sections and research for each and every point without showing any indeterminate of the company.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Up to 20% Discount on this Premium Report @

https://www.infinitybusinessinsights.com/request_sample.php?id=473646

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Infinity Business Insightsis a market research company that offers market and business research intelligence all around the world. We are specialized in offering the services in various industry verticals to recognize their highest-value chance, address their most analytical challenges, and alter their work.

We attain particular and niche demand of the industry while stabilize the quantum of standard with specified time and trace crucial movement at both the domestic and universal levels. The particular products and services provided by Infinity Business Insights cover vital technological, scientific and economic developments in industrial, pharmaceutical and high technology companies.

Contact Us:

Amit J

Sales Coordinator

+1-518-300-3575

amit@infinitybusinessinsights.com

https://mobile.twitter.com/IBInsightsLLP

https://facebook.com/Infinity-Business-Insights-352172809160429

https://www.linkedin.com/company/infinity-business-insights/

Read more:
Globel Mild To Moderate Plaque Psoriasis Market Scope and Forecast By 2021-2030 Allergan, Johnson and Johnson, Amgen, Abbvie, Eli Lilly, Dermira...

Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA)- Market Insight, Epidemiology and Market Forecast -2030

The global market for Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) estimated at USD XX million in the year 2020, is projected to reach a revised size of USD XX million by 2027, growing at a CAGR of XX % over the analysis period 2020-2027. The report provides the analysis of the Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) market across different regions.

It aims at estimating the market size and future growth potential of this market across different segments such as form, end-use industry, and type. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, SWOT analysis, recent developments, and key market strategies.

Get sample copy of thisreport @

https://www.infinitybusinessinsights.com/request_sample.php?id=473652

TOP Key Players @ Allergan, Johnson and Johnson, Amgen, Abbvie, Eli Lilly, Dermira Inc., Novartis, Galectin Therapeutics, Cellceutix Corporation and Biogen Inc., Bayer.

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

Global Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market: Regional Segment Analysis

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key factors driving the Global Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market?

What are the key market trends impacting the growth of the Global Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market?

What are the challenges to market growth?

Who are the key vendors in the Global Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market?

What are the market opportunities and threats faced by the vendors in the Global Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market;

3.) The North American Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market;

4.) The European Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market;

5.) Market entry and investment feasibility;

6.) The report conclusion.

All the research report is made by using two techniques that are Primary and secondary research. There are various dynamic features of the business, like client need and feedback from the customers. Before (company name) curate any report, it has studied in-depth from all dynamic aspects such as industrial structure, application, classification, and definition.

The report focuses on some very essential points and gives a piece of full information about Revenue, production, price, and market share.

Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market report will enlist all sections and research for each and every point without showing any indeterminate of the company.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Up to 20% Discount on this Premium Report @

https://www.infinitybusinessinsights.com/request_sample.php?id=473652

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Infinity Business Insightsis a market research company that offers market and business research intelligence all around the world. We are specialized in offering the services in various industry verticals to recognize their highest-value chance, address their most analytical challenges, and alter their work.

We attain particular and niche demand of the industry while stabilize the quantum of standard with specified time and trace crucial movement at both the domestic and universal levels. The particular products and services provided by Infinity Business Insights cover vital technological, scientific and economic developments in industrial, pharmaceutical and high technology companies.

Contact Us:

Amit J

Sales Coordinator

+1-518-300-3575

amit@infinitybusinessinsights.com

https://mobile.twitter.com/IBInsightsLLP

https://facebook.com/Infinity-Business-Insights-352172809160429

https://www.linkedin.com/company/infinity-business-insights/

Here is the original post:
Moderate to Severe Plaque Psoriasis (ONLY CANADA DATA) Market Scope and Forecast By 2021 to 2028-Allergan, Johnson and Johnson, Amgen, Abbvie, Eli...

INDIANAPOLIS, June 1, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will present new data from Phase 3 studies that further demonstrated the long-term efficacy and safety profile of Taltz(ixekizumab) among patients with axial spondyloarthritis (axSpA). These results are being presented at the virtual Annual European Congress of Rheumatology (EULAR), June 2-5, 2021.

AxSpA is recognized as a single disease entity, with two subtypes which are defined depending on the presence (radiographic axSpA, or r-axSpA) or absence (non-radiographic axSpA, or nr-axSpA) of defined structural damage of the sacroiliac joints on plain x-ray films as per the modified New York (mNY) criteria.

"Patients living with axial spondyloarthritis deal with a range of chronic, debilitating symptoms, including inflammatory back pain, and are in need of treatment options that can provide long-term efficacy," said Lotus Mallbris, M.D., Ph.D., vice president of immunology development at Lilly. "We are excited to present a range of new data at EULAR that demonstrate treatment with Taltz provides consistent, long-term efficacy on common signs and symptoms over time in axial spondyloarthritis."

Taltz Showed Sustained Long-Term Improvements in axSpA Through Two Years

In COAST-Y, Taltz showed consistent and sustained long-term improvements in signs and symptoms, functionality and quality of life in patients with r- and nr-axSpA. In this study, more than half of patients (56.7%) treated continuously with Taltz (80 mg every four weeks, n=157) through two years achieved Assessment of SpondyloArthritis international Society 40% response (ASAS40).

Among those treated continuously with Taltz every four weeks for two years:

The safety profile of Taltz was consistent with previously published safety data, and no new safety signals were observed after up to two years of treatment.

For methodology, see the "About the Analyses" section below. Additional results from the Phase 3 COAST-Y study were also recently published in the Annals of the Rheumatic Diseases.

Most Patients Treated with Taltz Did Not Show Bone Damage Progression of r-axSpA Up to Two Years

An analysis of two Phase 3 studies in r-axSpA (COAST-V and COAST-W) and the long-term extension trial (COAST-Y), found that 9 out of 10 patients treated with Taltz (89.6%, n=206) did not show radiographic progression for up to two years, as measured by mean change from baseline of modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) <2. Overall mean rates of progression were low among patients treated with Taltz. These results were similar among patients who were previously treated with anti-TNF therapy (88%, n= 106) and those who had not previously been treated with a biologic (91%, n=100). For methodology, see the "About the Analyses" section below.

"If left uncontrolled, individuals living with active radiographic axSpA can experience severe, chronic pain and structural damage in the spine that can lead to fusion of the spine and loss of mobility," said Walter P. Maksymowych, M.D., FRCP (C), Professor of Medicine at the University of Alberta, and Chief Medical Officer, CARE Arthritis, Edmonton, CA, and the senior author of this analysis. "Most patients treated with ixekizumab did not show structural damage progression at two years, and the degree of progression was small. In addition to known predictors, the novel finding is that attainment of remission of inflammation on MRI at one year protected from progression at two years."

Notably, Lilly will also present new analyses in axSpA and psoriatic arthritis, including the following:

More than 175,000 patients have been treated with Taltz worldwide since launch, giving healthcare providers confidence in making informed prescribing decisions for the treatment of adults with active psoriatic arthritis, active ankylosing spondylitis, active nr-axSpA and moderate to severe plaque psoriasis.

About the Analyses

INDICATIONS AND USAGE FOR TALTZ Taltz is approved for the treatment of patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy and for the treatment of adults with active psoriatic arthritis, active ankylosing spondylitis, or active non-radiographic axial spondyloarthritis with objective signs of inflammation.

IMPORTANT SAFETY INFORMATION FOR TALTZ

CONTRAINDICATIONSTaltz is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.

WARNINGS AND PRECAUTIONS InfectionsTaltz may increase the risk of infection. In clinical trials of adult patients with plaque psoriasis, the Taltz group had a higher rate of infections than the placebo group (27% vs 23%). A similar increase in risk of infection was seen in placebo-controlled trials of adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis. Serious infections have occurred. Instruct patients to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a serious infection develops, discontinue Taltz until the infection resolves.

Pre-Treatment Evaluation for Tuberculosis Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with Taltz. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering Taltz. Closely monitor patients receiving Taltz for signs and symptoms of active TB during and after treatment.

Hypersensitivity Serious hypersensitivity reactions, including angioedema and urticaria (each 0.1%), occurred in the Taltz group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in post-marketing use with Taltz. If a serious hypersensitivity reaction occurs, discontinue Taltz immediately and initiate appropriate therapy.

Inflammatory Bowel Disease Patients treated with Taltz may be at an increased risk of inflammatory bowel disease. In clinical trials, Crohn's disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the Taltz group than the placebo group. During Taltz treatment, monitor patients for onset or exacerbations of inflammatory bowel disease and if IBD occurs, discontinue Taltz and initiate appropriate medical management.

Immunizations Prior to initiating therapy with Taltz, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with Taltz.

ADVERSE REACTIONS Most common adverse reactions (1%) associated with Taltz treatment are injection site reactions, upper respiratory tract infections, nausea, oropharingeal pain and tinea infections. Overall, the safety profiles observed in adult patients with psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, and pediatric patients with plaque psoriasis were consistent with the safety profile in adult patients with plaque psoriasis, with the exception of influenza and conjunctivitis in psoriatic arthritis and conjunctivitis, influenza, and urticaria in pediatric psoriasis (also common). Adverse drug reactions in patients with radiographic axial spondyloarthritis (ankylosing spondylitis) were similar with the exception of inflammatory bowel disease (common) and rhinitis (common). In patients with non-radiographic axial spondyloarthritis, adverse events were also similar to inflammatory bowel disease (common), influenza (common) and conjunctivitis (common).

Please see full Prescribing Information and Medication Guide for Taltz. See Instructions for Use included with the device.

IX HCP ISI 07MAY2020

About TaltzTaltz is a monoclonal antibody that selectively binds with interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor.IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses.Taltz inhibits the release of pro-inflammatory cytokines and chemokines.

About Axial SpondlyoarthritisAxial spondyloarthritis (axSpA), which includes both radiographic axSpA (r-axSpA) and non-radiographic axSpA (nr-axSpA), is a disease predominantly affecting the sacroiliac joints and the spine. Common symptoms include chronic inflammatory back pain, fatigue and stiffness.1,2,3It is estimated that 2.3 million people in the U.S. have axSpA, and approximately half of those individuals live with nr-axSpA.2,4For patients with r-axSpA, the disease is characterized by the presence of structural damage of the sacroiliac joints that appears on an X-ray, while patients with nr-axSpA do not have clearly detectable structural damage radiographically.5These two patient subsets share a similar burden of disease and similar clinical features, but approved biologic treatment options for patients with nr-axSpA are much more limited and patients are often underdiagnosed.5,6

About Lilly in ImmunologyLilly is bringing our heritage of championing groundbreaking, novel science to immunology and is driven to change what's possible for people living with autoimmune diseases. There are still significant unmet needs, as well as personal and societal costs, for people living with a variety of autoimmune diseases and our goal is to minimize the burden of disease. Lilly is investing in leading-edge clinical approaches across its immunology portfolio in hopes of transforming the autoimmune disease treatment experience. We've built a deep pipeline and are focused on advancing cutting edge science to find new treatments that offer meaningful improvements to support the people and the communities we serve.

About Eli Lilly and CompanyLilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/news. P-LLY

Lilly Forward-Looking StatementThis press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Taltz (ixekizumab) as a treatment for ankylosing spondylitis, radiographic and non-radiographic axial spondylorarthritis, and psoriatric arthritis, and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of development and commercialization. Among other things, there can be no guarantee that Taltz will receive additional regulatory approvals or be commercially successful. For further discussion of these and other risks and uncertainties, see Lilly's most recent Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release.

1 Reveille JD, et al. Prevalence of axial spondylarthritis in the United States: Estimates from a cross-sectional survey. Arthritis Care Res. 2012;64(6):905-910.

2 Strand V, et al. Prevalence of axial spondyloarthritis in United States rheumatology practices: Assessment of SpondyloArthritis International Society criteria versus rheumatology expert clinical diagnosis. Arthritis Care Res. 2013;65(8):1299-306.

3 Kiltz U, et al. Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res. 2012;64(9):1415-22.

4 U.S. Census Bureau, Population Estimates Program (PEP) https://www.census.gov/quickfacts/fact/table/US# accessed on April 30, 2020.

5 Deodhar A, et al. The concept of axial spondyloarthritis: joint statement of the spondyloarthritis research and treatment network and the Assessment of SpondyloArthritis International Society in response to the US Food and Drug Administration's comments and concerns. Arth Rheum. 2014;66(10):2649-2656.

6 De Miguel Mendieta E, et al. Ann Rhuem Dis. 2018;77:1156. Abstract AB0857.

# # #

SOURCE Eli Lilly and Company

https://www.lilly.com/

Read more:
Taltz Showed Consistent, Long-Term Improvement in Key Signs and Symptoms of Axial Spondyloarthritis Through Two Years in Phase 3 Study - PRNewswire

Moderate Psoriasis- Market Insight, Epidemiology and Market Forecast -2030

The global market for Moderate Psoriasis estimated at USD XX million in the year 2020, is projected to reach a revised size of USD XX million by 2027, growing at a CAGR of XX % over the analysis period 2020-2027. The report provides the analysis of the Moderate Psoriasis market across different regions.

It aims at estimating the market size and future growth potential of this market across different segments such as form, end-use industry, and type. Furthermore, the report also includes an in-depth competitive analysis of the key players in the market along with their company profiles, SWOT analysis, recent developments, and key market strategies.

Get sample copy of thisreport @

https://www.infinitybusinessinsights.com/request_sample.php?id=473649

TOP Key Players @ Merck & Co., Abb Vie Inc., Amgen Inc., Eli Lilly & company, Sun Pharmaceutical Industries Ltd, Novartis International AG, Janssen Biotech Inc., Pfizer Inc., and Boehringer Ingelheim GmbH, among others.

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of Moderate Psoriasis market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

Global Moderate Psoriasis Market: Regional Segment Analysis

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they Moderate Psoriasis Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key factors driving the Global Moderate Psoriasis Market?

What are the key market trends impacting the growth of the Global Moderate Psoriasis Market?

What are the challenges to market growth?

Who are the key vendors in the Global Moderate Psoriasis Market?

What are the market opportunities and threats faced by the vendors in the Global Moderate Psoriasis Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia Moderate Psoriasis Market;

3.) The North American Moderate Psoriasis Market;

4.) The European Moderate Psoriasis Market;

5.) Market entry and investment feasibility;

6.) The report conclusion.

All the research report is made by using two techniques that are Primary and secondary research. There are various dynamic features of the business, like client need and feedback from the customers. Before (company name) curate any report, it has studied in-depth from all dynamic aspects such as industrial structure, application, classification, and definition.

The report focuses on some very essential points and gives a piece of full information about Revenue, production, price, and market share.

Moderate Psoriasis Market report will enlist all sections and research for each and every point without showing any indeterminate of the company.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Up to 20% Discount on this Premium Report @

https://www.infinitybusinessinsights.com/request_sample.php?id=473649

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:

Infinity Business Insightsis a market research company that offers market and business research intelligence all around the world. We are specialized in offering the services in various industry verticals to recognize their highest-value chance, address their most analytical challenges, and alter their work.

We attain particular and niche demand of the industry while stabilize the quantum of standard with specified time and trace crucial movement at both the domestic and universal levels. The particular products and services provided by Infinity Business Insights cover vital technological, scientific and economic developments in industrial, pharmaceutical and high technology companies.

Contact Us:

Amit J

Sales Coordinator

+1-518-300-3575

amit@infinitybusinessinsights.com

https://mobile.twitter.com/IBInsightsLLP

https://facebook.com/Infinity-Business-Insights-352172809160429

https://www.linkedin.com/company/infinity-business-insights/

The rest is here:
Moderate Psoriasis Market Scope and Forecast By 2021 to 2028-Merck & Co., Abb Vie Inc., Amgen Inc., Eli Lilly & company, Sun Pharmaceutical...

() Stuart Ashman joins Proactive London to discuss results from a study of people suffering from psoriasis that received its immune system-modulating food supplement delivering results that exceeded expectations.

In all 91 people with the condition completed the 56-day self-managed consumer study with 76% of the group reporting their skin felt less itchy, and 75% saying it appeared less red.

Ashman says the findings from the assessment of AxisBiotix-Ps, developed in collaboration with partner Winclove Probiotics, will pave the way for a commercial launch of the product in the fourth quarter.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of named herein, including the promotion by the Company of in any Content on the Site, the Company receives from said issuer annual cash...

See the original post:
SkinBioTherapeutics "delighted" with psoriasis study results, with 76% reporting less itchy skin - Proactive Investors UK

Psoriasis Therapeutics Market Research Report by Molecule (Biologics and Small Molecules), by Route of Administration (Oral, Parenteral, and Topical), by Dosage Forms, by Mechanism of Action - Global Forecast to 2025 - Cumulative Impact of COVID-19

New York, May 28, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Psoriasis Therapeutics Market Research Report by Molecule, by Route of Administration, by Dosage Forms, by Mechanism of Action - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05911318/?utm_source=GNW

Market Statistics:The report provides market sizing and forecast across five major currencies - USD, EUR GBP, JPY, and AUD. This helps organization leaders make better decisions when currency exchange data is readily available.

1. The Global Psoriasis Therapeutics Market is expected to grow from USD 16,490.57 Million in 2020 to USD 25,080.12 Million by the end of 2025.2. The Global Psoriasis Therapeutics Market is expected to grow from EUR 14,459.24 Million in 2020 to EUR 21,990.72 Million by the end of 2025.3. The Global Psoriasis Therapeutics Market is expected to grow from GBP 12,854.30 Million in 2020 to GBP 19,549.80 Million by the end of 2025.4. The Global Psoriasis Therapeutics Market is expected to grow from JPY 1,759,961.98 Million in 2020 to JPY 2,676,684.84 Million by the end of 2025.5. The Global Psoriasis Therapeutics Market is expected to grow from AUD 23,946.50 Million in 2020 to AUD 36,419.67 Million by the end of 2025.

Market Segmentation & Coverage:This research report categorizes the Psoriasis Therapeutics to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Molecule, the Psoriasis Therapeutics Market studied across Biologics and Small Molecules.

Based on Route of Administration, the Psoriasis Therapeutics Market studied across Oral, Parenteral, and Topical.

Based on Dosage Forms, the Psoriasis Therapeutics Market studied across Liquid, Semi-solid, and Solid.

Based on Mechanism of Action, the Psoriasis Therapeutics Market studied across IL blocker, PDE4 Inhibitors, and TNF Inhibitors.

Based on Geography, the Psoriasis Therapeutics Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Psoriasis Therapeutics Market including AbbVie Inc., Amgen, Inc., AstraZeneca, Celgene Corporation, Eli Lilly and Company, Johnson & Johnson, and Novartis AG.

Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Psoriasis Therapeutics Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:1. What is the market size and forecast of the Global Psoriasis Therapeutics Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Psoriasis Therapeutics Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Psoriasis Therapeutics Market?4. What is the competitive strategic window for opportunities in the Global Psoriasis Therapeutics Market?5. What are the technology trends and regulatory frameworks in the Global Psoriasis Therapeutics Market?6. What are the modes and strategic moves considered suitable for entering the Global Psoriasis Therapeutics Market?Read the full report: https://www.reportlinker.com/p05911318/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Story continues

See the article here:
Psoriasis Therapeutics Market Research Report by Molecule, by Route of Administration, by Dosage Forms, by Mechanism of Action - Global Forecast to...

A fish pedicure involves dipping the feet into a basin of water filled with fish. These fish, Garra rufa, sometimes called doctor fish, eat the dead skin off the feet revealing smooth, callous-free skin, and cleaner-looking cuticles.

Fish pedicures are popular in Turkey, where they originated, and other Middle Eastern countries. Garra rufa fish are native to the Middle East and Southeast Asian countries. They are allowed in certain places in the United States.

The procedure became popular because the fish are able to exfoliate and soften the feet in a non-painful way. The fish pedicure tickles but does not hurt. However, these pedicures pose both health and environmental risks, and are actually banned in many U.S. states and parts of Canada and Europe.

There are several reasons fish pedicures may be considered risky or unsafe. Here are the safety concerns of fish pedicures:

The purported benefits of fish pedicures include reduced callouses, smooth skin on the feet, and exfoliation of dry skin and rough patches. A pedicure done by a human from a trusted salon will do the same, however, and so will at-home use of a pumice stone or a foot scrub. The risks of fish pedicures outweigh the benefits.

One study found a 72 percent reduction of psoriasis in people undergoing ichthyotherapy, or using Garra rufa to treat conditions, though there are other treatments that dont carry risks.

At least 14 states have banned fish pedicures, including:

They are also banned in Mexico, parts of Europe, and parts of Canada.

There are also ethical concerns associated with fish pedicures.

Fish pedicures at a salon involve putting the feet in a basin of water filled with Garra rufa, a fish native to the Middle East. The purported benefits are smoother feet and potentially less psoriasis, but the safety and ethical concerns including potential for infection and lack of sanitation between customers outweigh the benefits.

Read more here:
Fish Pedicure: Risks, Benefits, Safety, and Ethical Concerns - Healthline

For years, I have been telling my patients your scalp is skin, so treat it well. Now, we are witness to a skinificaton of hair products and it is all because the scalp is a very important part of the hair growth process.

Healthy hair cannot be produced without a healthy scalp. The scalp skin is an extension of internal and external health. As I noted in a previous column (January 2020) the gut microbiome affects the skin microbiome which, in turn, affects the scalp microbiome, and therefore hair growth. Since 2020, we have witnessed the burgeoning of scalp care products with CBD formulations, products boasting microbiome benefits, and scalp serums and solutions for flaking, itching and tension. So, what is this all about? Lets dig into the science.

The surface of human skin is a site of microbial colonization. The commensal flora of the skin maintain a symbiotic relationship and shape the cutaneous immunity of the host. Several studies have characterized the cutaneous bacterial communities of healthy individuals and patients with inflammatory diseases, mostly in material collected using swabs. Sampling from hair follicle (HF) openings is challenging. Along their epithelium, HFs harbor a multitude of microorganisms able to reach deeper compartments, frequently organized in biofilms. The role of bacteria as disease-aggravating factors has been recognized for HF-associated inflammatory diseases such as acne vulgaris or folliculitis decalvans, an inflammatory, scarring hair loss.

Scalp hair follicles form large tubular invaginations, which extend deeply into the skin and harbor a variety of microorganisms. A single square centimeter of human skin, along with adnexal structures, such as sweat and oil glands, can be inhabited by up to one billion microorganisms including bacteria, fungi and viruses, forming a complex community known as the skin microbiome.

The scalp includes 100,000150,000 hair follicles (HFs); for comparison, the human body has about five million HFs. These follicles are formed during embryogenesis and ensure cyclic hair growth throughout ones lifetime. Those on the scalp contribute to a significant increase of skin surface area and, more importantly with regard to colonization, form pockets along the infundibulum, which extend into deeper scalp skin layers. The infundibulum is the upper portion of the hair follicle. It begins at the surface of the epidermis and extends to the opening of the sebaceous duct (where scalp oil is secreted). The infundibulum is typically filled with sebum, debris and microorganisms ranging from viruses to bacteria, as well as yeasts/fungi and even mites.

There is increasing proof of the presence of bacteria reaching below the skin surface and along the HFs, and evidence is emerging that the cross-talk between bacteria and the underlying tissue is a dynamic reciprocal process. External microbial stimuli create immunological responses across the HF epithelium, but events in the tissue also shape microbial composition. Along the infundibular HF epithelium, microorganisms find themselves in a highly immuno-active environment. In contrast to the massive exposure to microbial material in its upper part, immuneprivileged sites are found around the hair bulge and the anagen bulb. The bulge contains several epidermal stem cells. A collapse of the immune privilege is a key element in the pathogenesis of chronic scalp diseases. Numerous immune cells are deployed in the skin and around its appendages in close proximity to microbiota. Commensals are considered essential to maintain skin homoeostasis. They protect the skin from its colonization by pathogens, stimulate production of the complement system and cytokines involved in the initiation and maintenance of an immune response. Furthermore, microbiota help decrease the magnitude of inflammation and promote tissue repair.

Acne and primary scarring alopecias are good examples of how the local follicular microenvironment; e.g., hypoxic conditions and lipid substrates, resident microbes and their metabolic products, can influence inflammatory and antimicrobial processes in the skin.

The skin surface and follicular openings are recognized sites of rich microbial colonization and intense immune activation, with cross-talk across the skin barrier. The bacterial microbiome extends below the infundibulum, with the confirmed presence of various species and high abundance of Corynebacterium and Staphylococcus. It is in close proximity to structures of the immune privileged status, which are essential for the hair cycle.

Several preliminary studies suggest that external stimuli may affect the state of activation of the HF immune system. Lower sections of the HF are protected from immune cell infiltration under healthy conditions, the so-called immune-privileged areas. This includes the bulge, where a stem cell niche is found, and the bulb, where cells divide and grow to build the new hair. However, both regions are sites of intense inflammatory infiltrate in inflammatory hair diseases like primary cicatricial alopecia and alopecia areata. Alterations in the HF microbiome or the penetration depth of microbial material could be related to homeostasis, modulation of cutaneous immune reactions and inflammatory processes along the HF. The localization of this involvement with the immune system is critical, affecting the possibility of regrowth after subsidence of inflammation. When the stem cell niche is attacked, like in cicatricial alopecia, patients suffer permanent, scarring hair loss. On the other hand, AA pathogenesis involves inflammation of the peribulbar region, allowing a possible hair regrowth.

The strongest evidence supporting correlations with microorganisms colonizing the scalp has been found in seborrheic dermatitis/dandruff and in a type of inflammatory cicatricial alopecia named folliculitis decalvans (FD). An antimicrobial treatment administered in these diseases brings transient success in most cases. However, frequent recurrences, lack of efficacy in some patients and the additional need of antiinflammatory therapy in acute flareups, indicate the complexity of their pathogenesis.

Androgenetic alopecia (AGA) features shortening of the anagen phase and eventually, a slowly progressing miniaturization of the hair follicle. Infiltration of mononuclear cells and lymphocytes is detected in about 50% of skin samples. This microinflammation takes place in the upper third of the HF, where a great number of microorganisms are harbored. Moreover, the production of complement (inflammatory mediators), were identified in the pilosebaceous duct of 58% of patients with AGA compared to 12% of the control group. These arguments together with observed improvement after application of antimicrobial agents may suggest a possible connection with scalp microflora.

In scalp psoriasis, the rate of positive cultures of Malassezia species was higher in psoriatic scalp lesions compared to healthy controls. Changes of the scalp microbiome were found to depend on disease severity. GomezMoyano et al. identified M. restricta as the most frequent in mild scalp psoriasis, and M. globosa in moderate, and severe cases, and in patients with exacerbation in the last month. Cases of refractory scalp psoriasis successfully treated with imidazole, followed by reduction of yeasts, were presented and support the theory of a role of Malassezia as an exacerbating factor in scalp psoriasis. Furthermore, alterations in the composition of gut microbiome have been observed in patients with psoriasis.

A possible connection between colonization of the scalp by Alternaria spp. and Alopecia Areata (AA) development was postulated. Fungi of this genus were cultured from epidermal scrapings in 20% of patients compared to 13.3% of controls. Not only skin but also gut microbiome has recently been considered to be associated with AA. An increased intestinal permeability due to dysbiosis and/or inflammation may be an underlying stressor of the immune system in genetically susceptible individuals.

Low production of short chain fatty acids by intestinal bacteria as a result of insufficient intake of fibers in the Western diet is likely disadvantageous to the intestinal barrier and function of the colon. This further supports the idea that a healthy gut is important in maintaining healthy skin and hair.

There is a greater prevalence of atopic dermatitis in patients with AA compared to population prevalence. Atopic dermatitis is associated with more severe course of AA. The defective skin barrier in atopic dermatitis may ease microbial penetration to deeper follicular compartments, possibly aggravating or causing alopecia areata.

So why the skinification of hair care? The aforementioned diseases of the skin and the HFs are all due to dysfunctions of dysbiosisthe imbalance of the skin microbiome. Skin barrier dysfunction translates into scalp barrier dysfunction, leading to inflammation and hair loss as evidenced by the link between eczema and more severe alopecia areata.

Just as it is important to maintain the skin barrier with ceramides and lipids, it is important to maintain the scalp barrier as well with scalp and hair care products that mimic skin care products. It only makes sense, as the scalp is a continuation of the skin. There is no line of demarcation separating bodily skin from scalp, so why not care for your scalp as you do for your skin?

References

Dr. Sharleen St. Surin-Lord is a board-certified dermatologist who has been practicing for more than 13 years. She is in private practice at Visage Dermatology, Largo MD. She also practices at the University of Maryland Capital Regional Health System in Maryland and she is an assistant professor of dermatology at Howard University College of Medicine. Dr. Sharleen is a member of the American Hair Research Society and you can follow her on Twitter, Instagram, and Facebook as DermHairDoc.

See the original post:
The 'Skinification' Of Hair Care - HAPPI - happi.com

Authors of a case report called for investigation of the possible relationship between nonischemic dilated cardiomyopathy (NIDCM) and psoriasis after they treated a man with the rare combination of diseases.

The case involved an active 58-year-old man with a history of untreated psoriasis and psoriatic arthritis (PsA) who presented with a sudden onset of shortness of breath in the emergency department, according to clinicians from a New Jersey hospital in The American Journal of Case Reports. The patient was ultimately diagnosed with acute congestive heart failure secondary to NIDCM.

The patient responded well to diuretics and was placed on guideline-directed medical therapy during his inpatient stay and was later treated with secukinumab (Cosentyx) for psoriasis. Three months later, his cardiac symptoms had improved and his psoriatic skin lesions had resolved; repeat echocardiography showed improvement in his ejection fraction (EF).

Studies have shown the prevalence of cardiovascular risk factors and diseases is higher in patients with psoriasis, especially in those with PsA. However, the authors said, reports are rare in psoriasis patients of nonischemic cardiomyopathy, especially dilated cardiomyopathy, which involves enlargement and weakening of the left ventricle. In the literature available, an association between psoriasis and NIDCM has been increasingly reported, with the incidence of DCM reported as 10 times higher in patients with psoriasis.

The authors urged clinicians of psoriasis patients to be aware of a higher risk of cardiovascular events, counsel them on the importance of eliminating traditional risk factors for cardiovascular disease such as obesity and smoking, and institute early treatment with antipsoriasis agents to reduce heart disease and prevent death.

The patient entered the hospital with extensive skin psoriasis (more than 50% of the body) with deformities in the joints of his hands and feet caused by PsA. Laboratory results were remarkable only for B-type natriuretic peptide (BNP) at 865 ph/mL (normal value 0-100 pg/mL). An electrocardiogram showed sinus tachycardia with left bundle branch block, and chest X-ray revealed acute bilateral pulmonary edema. The patient was placed on bilevel positive airway pressure and received furosemide (Lasix) and a beta blocker (labetalol). An echocardiogram the following day showed severely reduced left ventricular systolic function with an ejection fraction (EF) of 21% to 25%, grade III (severe) diastolic dysfunction, and severe global hypokinesis.

Treating physicians determined that either interleukin-17 (IL-17) or IL-12/23 inhibitors, or phosphodiesterase-4 inhibitor, were necessary to treat the psoriasis. Tumor necrosis factor inhibitors were avoided due to heart disease and low EF. The patient responded well to diuretics; was placed on losartan (Cozaar), cavedilol (Coreg), and spironolactone; and discharged with a defibrillator.

A cardiac MRI upon follow-up showed mild biventricular nonischemic cardiomyopathy.

At a 2-week follow-up with a rheumatologist, the patient was placed on secukinumab, a monoclonal antibody that inhibits IL-17A, via injection at a dosage of 300 mg weekly for 5 weeks and monthly thereafter.

A 3-month follow-up showed significant improvement in cardiac symptoms, with a normal BNP level, resolution of psoriatic skin lesions, and an EF of 41% to 45% on a repeat echocardiogram.

Reference

Alfraji N, Douedi S, Alshami A, et al. Nonischemic dilated cardiomyopathy in untreated long-term psoriatic arthritis: a newly recognized association: A case report with mini review. Am J Case Rep. Published online April 2, 2021. doi:10.12659/AJCR.930041

See more here:
Untreated Psoriasis and a Cardiac Connection: Lessons From a Case Report - AJMC.com Managed Markets Network

Generalized pustular psoriasis (GPP) may have therapies in a few years; how patients define remission in psoriatic arthritis (PsA).

Generalized pustular psoriasis (GPP) might be considered as a rare, angrier variant of psoriasis, according to a dermatologist presenting at a recent symposium.

However, Dermatology Times reported that there are no FDA-approved therapies for the disease; current treatments are off-label. That means they arent as accessible to patients given insurance policies around off-label use, said Bruce Strober, MD, PhD, cofounder of Central Connecticut Dermatology in Cromwell and clinical professor of dermatology at Yale School of Medicine in New Haven, Connecticut.

At the Symposium for Inflammatory Skin Disease last month, he spoke about targeted drugs that are in the early stages of development for GPP, including imsidolimab and spesolimab, both of which inhibit interleukin (IL)-36R; they are currently showing promise in phase 1 and phase 2 trials, he said.

Severe GPP can cause diffuse sterile pustules, significant skin pain, and systemic complaints such as fever, fatigue, and metabolic abnormalities.

Read more about the report in Dermatology Times.

Disease impact and disease activity are factors identified with the concept of patient-defined remission in psoriatic arthritis (PsA), according to a recent study.

Reported by Rheumatology Network, researchers used study data from ReFlaP data, an international PsA study. In PsA, the treatment goal is remission (REM) or low disease activity (LDA), but information about what patients think about REM is lacking.

In patients with PsA, patient-defined remission (REM) and low disease activity (LDA) are largely dominated by disease impact, including pain, as well as disease activity, chronicity and age, comorbidities, and symptoms related to other conditions, according to the results.

Read more about the study in Rheumatology Network.

Excerpt from:
Psoriasis Recap: Investigational Therapies for GPP; How Patients View Remission in PsA - AJMC.com Managed Markets Network